Key takeaways
- Anthropic said on October 27 that it acquired Mithril Medicine, a one-person company working on two rare forms of muscular dystrophy.
- It reported early, mostly preclinical results from partnerships with six drug developers, including Bristol Myers Squibb and Enveda.
- Anthropic says one Mithril candidate could reach human trials as early as late 2028; no deal price was given.
Anthropic said on October 27 that it has acquired Mithril Medicine, a one-person company developing treatments for two rare forms of muscular dystrophy, and published early results from its drug development work with Claude. The results come from partnerships with six drug developers. Nearly all of the work is preclinical, which means it has not been tested in people.
Anthropic is now running its own drug discovery programs, not only supplying a model to partners. That moves it from tool vendor toward drug developer, and it raises the bar for how its claims should be read. Every result below is Anthropic's own account, and none has been independently reviewed.
What the six partners did
Anthropic reports these results from its life sciences team's partnerships:
- Generate Biomedicines used Claude Code to propose shorter versions of one genetic component in a CAR T-cell therapy, a treatment that has mostly worked against blood cancers. One design was about 70% shorter. In lab tests, the immune cells made roughly 10 times as many receptors, killed tumor cells more efficiently and stayed active longer.
- Divergence Labs is working on a food allergy treatment that removes IgE, the antibody behind allergic reactions, from immune cells. Claude produced about 35,000 antibody designs in roughly a month. Early tests found three binders and 20 designs that could dislodge IgE, three of which did it better than the standard medication.
- BigHat Biosciences connected Claude to its lab data system and tested about 1,010 antibody-fragment variants over roughly 10 weeks. The best versions bound more than 10 times more tightly. Anthropic says Claude and one of its researchers found that the usual stability metrics were misleading, and the lab validated better ones.
- Enveda used Claude on manufacturing paperwork. Claude reviewed 1,061 pages, caught all 11 issues human reviewers found and flagged seven they missed. Human review time fell 89%, from over 25 hours to under three.
- The Column Group is forming a new company, Pleiades, to run drug programs with Claude. Its first Claude skill, which judges whether a drug target is worth pursuing, was tested on 45 target-disease pairs.
- Bristol Myers Squibb is a newer partner. Claude helps assess clinical trial plans for an early-stage drug and estimate their chance of success. BMS plans to expand the work in 2027.
The Mithril Medicine acquisition
Mithril's founder, Cody Tranbarger, used Claude to organize contracts, logistics and experiments across 11 outside labs. Anthropic says a possible treatment for one of the two diseases went from idea to promising mouse results in under 18 months. Tranbarger now works at Anthropic and is planning new programs. The company gave no price for the deal. It says that if the candidates keep performing, one could enter human trials as early as late 2028.
What we don't know yet
Anthropic says the results are early and not proof of effective new medicines. Most candidates have not been tested in humans, and most numbers come from the partners' own lab work or Anthropic's reporting of it. The post does not give a purchase price or deal terms for Mithril.
Watch for the first clinical-stage partner. Anthropic says it plans to extend Claude into clinical trials once programs get that far. For the company's other public numbers, see our report on its IPO filing.
